# Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer

Source: https://onco.cc/trials/nct05261750/  
OnCo record `nct05261750` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) in nasopharyngeal carcinoma, run by PT. Prodia Stem Cell Indonesia, active and no longer recruiting.

## Summary

Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer is a phase 1/2 interventional study registered as NCT05261750 by PT. Prodia Stem Cell Indonesia, with 15 participants enrolled, started 2022-04-30 and due to reach its primary completion in 2026-02-28. Interventions recorded: Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) and Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05261750
- Phase: 1/2
- Setting: Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
- Sponsor: PT. Prodia Stem Cell Indonesia
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT05261750: https://clinicaltrials.gov/study/NCT05261750

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/)

---
JSON: https://onco.cc/api/v1/entities/nct05261750.json